


## PHARMACEUTICAL 2021



## ALNYLAM PHARMACEUTICALS INC. Alnylam 20 Rank 173 of 409







PHARMACEUTICAL 2021



## ALNYLAM PHARMACEUTICALS INC. <sup>2</sup>Alnylam<sup>®</sup>20 Rank 173 of 409

The relative strengths and weaknesses of ALNYLAM PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALNYLAM PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 59% points. The greatest weakness of ALNYLAM PHARMACEUTICALS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is -82%, being 273% points above the market average of -355%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 2,614,777         |
| Cost of Goods Sold                          | 78,052            |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 585,270           |
| Liabilities, Non-Current                    | 556,041           |
| Other Assets                                | 327,255           |
| Other Compr. Net Income                     | -7,104            |
| Other Expenses                              | 2,681             |
| Other Liabilities                           | 1,249,503         |
| Other Net Income                            | -27,162           |
| Property and Equipment                      | 465,029           |
| Research and Development                    | 654,819           |
| Revenues                                    | 492,853           |
| Selling, General and Administrative Expense | 588,420           |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 3,407,061         |
| Liabilities              | 2,390,814         |
| Expenses                 | 1,323,972         |
| Stockholders Equity      | 1,016,247         |
| Net Income               | -858,281          |
| Comprehensive Net Income | -861,833          |
| Economic Capital Ratio   | -82%              |

